These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 19136678)

  • 41. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
    Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
    Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
    Deforche K; Camacho R; Grossman Z; Silander T; Soares MA; Moreau Y; Shafer RW; Van Laethem K; Carvalho AP; Wynhoven B; Cane P; Snoeck J; Clarke J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Shapiro JM; Katzenstein DA; Kantor R; Vandamme AM
    Infect Genet Evol; 2007 Jun; 7(3):382-90. PubMed ID: 17127103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates.
    Knops E; Däumer M; Awerkiew S; Kartashev V; Schülter E; Kutsev S; Brakier-Gingras L; Kaiser R; Pfister H; Verheyen J
    J Antimicrob Chemother; 2010 Jul; 65(7):1472-6. PubMed ID: 20430786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.
    Bessong PO
    Trop Med Int Health; 2008 Feb; 13(2):144-51. PubMed ID: 18304259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
    Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.
    Sevin AD; DeGruttola V; Nijhuis M; Schapiro JM; Foulkes AS; Para MF; Boucher CA
    J Infect Dis; 2000 Jul; 182(1):59-67. PubMed ID: 10882582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
    Svicher V; Ceccherini-Silberstein F; Erba F; Santoro M; Gori C; Bellocchi MC; Giannella S; Trotta MP; Monforte Ad; Antinori A; Perno CF
    Antimicrob Agents Chemother; 2005 May; 49(5):2015-25. PubMed ID: 15855527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
    Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
    J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G.
    Abecasis AB; Deforche K; Snoeck J; Bacheler LT; McKenna P; Carvalho AP; Gomes P; Camacho RJ; Vandamme AM
    AIDS; 2005 Nov; 19(16):1799-806. PubMed ID: 16227787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
    Krauchenco S; Martins NH; Sanches M; Polikarpov I
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):638-45. PubMed ID: 18825538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
    Scudeller L; Torti C; Quiros-Roldan E; Patroni A; Lo Caputo S; Moretti F; Mazzotta F; Donati E; Vivarelli A; Carosi G;
    J Antimicrob Chemother; 2003 Nov; 52(5):776-81. PubMed ID: 14563897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protease inhibition in African subtypes of HIV-1.
    Velázquez-Campoy A; Vega S; Fleming E; Bacha U; Sayed Y; Dirr HW; Freire E
    AIDS Rev; 2003; 5(3):165-71. PubMed ID: 14598565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
    Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
    J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
    Núńez M; de Mendoza C; Valer L; Casas E; López-Calvo S; Castro A; Rosón B; Podzamczer D; Rubio A; Berenguer J; Soriano V
    Med Sci Monit; 2002 Sep; 8(9):CR620-3. PubMed ID: 12218942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.